市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | AN2 Therapeutics, Inc. | 混合的 | 混合的 |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.9 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -5.0 |
| 相对估值 | NA |
| 财务健康 | -1.7 |
| 宏观环境 | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| 平均 | -1.83 |
|
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 22.90% |
| 机构持股比例 | 36.89% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Summittx Capital, L.P. | 30 Jun 2026 | 597,453 |
该时间范围内无数据。
该时间范围内无数据。
投资组合